Adrenocorticotropic hormone (ACTH) represents one of the most critical neuroendocrine signaling molecules governing mammalian homeostasis, behavioral adaptation, and physiological stress responses. Synthesized and secreted by the anterior pituitary gland, this polypeptide acts as the primary intermediary of the hypothalamic-pituitary-adrenal axis, translating central neural signals into systemic endocrine cascades. Understanding the biochemical structure, physiological regulation, and pathological dysregulation of ACTH provides foundational insights into endocrinology, clinical neuropsychiatry, and systemic human pathology.
Adrenocorticotropic Hormone (ACTH)
1. Concise Definition
Adrenocorticotropic hormone (ACTH), also known as corticotropin, is a 39-amino-acid peptide hormone synthesized and secreted by the corticotrope cells of the anterior pituitary gland. Its principal physiological function is to stimulate the adrenal cortex—specifically the zona fasciculata and zona reticularis—to produce and secrete glucocorticoids (predominantly cortisol in humans) and adrenal androgens.
As an essential component of the hypothalamic-pituitary-adrenal axis, ACTH release is triggered by hypothalamic corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP) in response to circadian rhythms and systemic physiological or psychological stressors. Once released into systemic circulation, ACTH binds with high affinity to the melanocortin 2 receptor (MC2R) on adrenocortical cells, initiating an intracellular cyclic adenosine monophosphate (cAMP) signaling cascade that drives steroidogenesis.
Beyond its classical steroidogenic action, ACTH exerts trophic maintenance effects on the structural integrity of the adrenal cortex. Pathological alterations in its secretion, whether through primary endocrine tumors, ectopic production, or hypothalamic dysfunction, lead to severe clinical syndromes such as Cushing syndrome and Addison disease, highlighting its indispensable role in biological equilibrium.
2. Etymology & Linguistic Origin
The term adrenocorticotropic is derived from classical linguistic roots reflecting its anatomical targets and physiological actions. The prefix ad- (Latin for “toward” or “near”) and ren (Latin for “kidney”) compose adrenal, indicating the glands situated adjacent to the kidneys. The root cortex (Latin for “bark” or “outer shell”) identifies the peripheral layer of these glands. The combining form -tropic stems from the Ancient Greek tropē (τροπή), meaning “a turning,” “direction,” or “inclination,” which in physiological nomenclature denotes an affinity for or a stimulating effect upon a specific tissue.
Thus, “adrenocorticotropic” literally translates to “directed toward or stimulating the adrenal cortex.” The alternative appellation, corticotropin, derives similarly from the Latin cortex combined with the Greek trophē (τροφή, meaning “nourishment” or “growth”), emphasizing the trophic and proliferative support the hormone confers upon adrenocortical tissues. The abbreviation ACTH entered common scientific parlance during the mid-twentieth century as biochemical isolation protocols clarified its molecular distinctiveness from other pituitary secretions.
3. Pronunciation & Grammatical Form
Pronunciation: /əˌdriːnoʊˌkɔːrtɪkoʊˈtroʊpɪk ˈhɔːrmoʊn/ (uh-DREE-noh-KOR-tih-koh-TROH-pik HOR-mohn). The abbreviated form ACTH is conventionally pronounced letter-by-letter as an initialism: /ˌeɪ siː tiː ˈeɪtʃ/ (A-C-T-H).
Grammatically, “adrenocorticotropic hormone” serves as a compound noun phrase. The term “adrenocorticotropic” functions as a non-gradable classifying adjective modifying the noun “hormone.” In clinical and research contexts, the synonymous single-word noun “corticotropin” is frequently employed. Derivatives include the adjective “adrenocorticotrophic” (an alternate spelling favored in older British literature) and “corticotropic,” referring to cells or actions related to corticotropin synthesis.
4. Detailed Conceptual Explanation
The operational dynamics of ACTH reside within an intricate neuroendocrine feedback circuit designed to preserve homeostasis amidst internal fluctuations and external threats. ACTH is produced via the post-translational processing of a larger precursor preprohormone known as pro-opiomelanocortin (POMC). Within the anterior pituitary corticotropes, POMC is cleaved by the endopeptidase prohormone convertase 1 (PC1/3) to yield ACTH(1-39), along with beta-lipotropin and an N-terminal peptide fragment. Biologically active ACTH consists of an unbranched single-chain polypeptide containing 39 amino acid residues; evolutionary conservation is remarkably high, with the biological activity residing almost entirely within the first 24 amino acids (ACTH 1-24), while residues 25-39 confer species specificity and metabolic stability.
The secretion of ACTH is governed by a prominent circadian rhythm and acute pulsatile bursts. Under unstressed conditions, circulating ACTH concentrations peak in the early morning hours (shortly before habitual awakening) and progressively decline throughout the day, reaching their nadir near midnight. Superimposed upon this circadian periodicity are rapid episodic secretory bursts synchronized with the pulsatile release of hypothalamic CRH and AVP into the hypophyseal portal system. In situations of acute stress—such as trauma, systemic infection, hypoglycemia, hypovolemia, or severe psychological threat—higher cortical and limbic centers override normative circadian inhibition, unleashing robust surges of CRH and AVP that precipitate immediate, massive elevations in circulating ACTH.
Upon reaching the adrenal gland, ACTH exerts its biological effects by binding to the melanocortin 2 receptor, a member of the G protein-coupled receptor (GPCR) superfamily uniquely dependent on the melanocortin receptor accessory protein (MRAP) for functional cell-surface trafficking and ligand recognition. Activation of the receptor stimulates adenylyl cyclase via the Gs alpha subunit, elevating intracellular cAMP and activating protein kinase A (PKA). This signal transduction pathway triggers acute and chronic cellular events: acutely, it stimulates the steroidogenic acute regulatory (StAR) protein to transport free cholesterol across the mitochondrial membrane—the rate-limiting step in steroidogenesis; chronically, it transcriptionally upregulates cytochrome P450 enzymes responsible for steroid synthesis and promotes cell hyperplasia and hypertrophy within the adrenal cortex.
Circulating glucocorticoids, particularly cortisol, exert profound negative feedback upon both the hypothalamus and the anterior pituitary. Cortisol binds to high-affinity glucocorticoid receptors (GR) within the corticotropes, directly suppressing POMC gene transcription and inhibiting the exocytosis of ACTH-containing secretory granules. Concurrently, cortisol suppresses CRH and AVP gene expression in the paraventricular nucleus of the hypothalamus. This closed-loop negative feedback architecture ensures that excessive glucocorticoid production is rapidly mitigated, protecting peripheral tissues from prolonged exposure to catabolic, immunosuppressive, and neurotoxic elevations of stress steroids.
5. Historical Development
The identification and characterization of ACTH unfolded across the first half of the twentieth century alongside the birth of modern endocrinology. In the late 1920s and early 1930s, pioneering anatomist and endocrinologist Philip E. Smith demonstrated through hypophysectomy experiments in rodents that surgical ablation of the pituitary gland induced profound atrophy of the adrenal cortex, which could be reversed by grafting pituitary tissue. Shortly thereafter, Harvey Cushing published his seminal 1932 monograph describing the clinical manifestations of pituitary basophilism—later termed Cushing disease—directly linking anterior pituitary hyperfunction to hypercortisolemia and bilateral adrenocortical hyperplasia.
During the 1940s, significant biochemical breakthroughs occurred. Independent research teams led by Choh Hao Li at the University of California, Berkeley, and George Sayers at the University of Utah successfully extracted and partially purified corticotropic fractions from animal pituitary glands. These crude extracts established that the adrenocortical-stimulating property resided in a distinct polypeptide hormone rather than a nonspecific protein derivative. The subsequent decade witnessed the complete structural elucidation and sequencing of the 39-amino-acid peptide by Li and his contemporaries in the mid-1950s, followed by the laboratory synthesis of biologically active ACTH fragments by Klaus Hofmann and Robert Schwyzer in the early 1960s.
The latter half of the twentieth century expanded understanding from molecular structure to regulatory genetics. In 1979, Shigetada Nakanishi and colleagues cloned and sequenced the cDNA of POMC, proving that ACTH, alpha-melanocyte-stimulating hormone (alpha-MSH), and beta-endorphin all share a single polyprotein precursor. In 1981, Wylie Vale and his team isolated and characterized CRH, illuminating the definitive hypothalamic trigger for ACTH release. The subsequent cloning of the melanocortin receptor family in the early 1990s provided the final structural link necessary to comprehend the receptor-level mechanisms through which ACTH directs adrenocortical physiology.
6. Theoretical Foundations
The conceptual framework encompassing ACTH is anchored within general systems theory and classical homeostatic models. Claude Bernard’s nineteenth-century postulate of the milieu intérieur and Walter Cannon’s twentieth-century operationalization of homeostasis established the biological premise that complex organisms must maintain physiological equilibrium in a dynamic environment. Within this paradigm, ACTH operates as an essential biological messenger within an error-correcting, negative-feedback control loop. Disturbances in internal equilibrium (such as falling blood glucose or dropping blood pressure) prompt immediate neuroendocrine responses where ACTH acts as an effector signal restoring homeostatic balance.
Hans Selye’s formulation of the General Adaptation Syndrome (GAS) positioned ACTH at the center of the physiological stress response. Selye argued that diverse noxious stimuli elicit a stereotypical physiological response characterized by three distinct stages: the alarm reaction, the stage of resistance, and the stage of exhaustion. ACTH constitutes the critical endocrine driver transitioning an organism from the immediate sympathetic “fight-or-flight” alarm state into the sustained metabolic resistance phase, mobilizing energy substrates via glucocorticoids to cope with persistent challenges.
In modern psychobiology, the concept of allostasis, introduced by Peter Sterling and Joseph Eyer and refined by Bruce McEwen, has expanded Selye’s framework. Allostasis conceptualizes how the body achieves stability through active physiological and behavioral change. Within allostatic theory, ACTH is viewed not merely as a homeostatic clamp, but as an adaptive mediator that shifts operational set-points based on anticipated demands. However, when the HPA axis is repeatedly or chronically activated, the persistent elevation or dysregulated cycling of ACTH and cortisol induces “allostatic load”—the cumulative physiological wear and tear that predisposes individuals to cardiovascular disease, metabolic syndrome, immune suppression, and psychiatric disorders.
7. Key Components, Types & Dimensions
The biological profile of ACTH can be categorized into distinct structural, functional, and physiological dimensions:
- Pro-opiomelanocortin (POMC) Precursor: The 241-amino-acid prohormone from which ACTH is derived via targeted proteolytic cleavage by prohormone convertase 1 (PC1/3) in pituitary corticotrope granules.
- Biologically Active N-Terminal Core (ACTH 1-24): The evolutionary conserved region of the hormone responsible for high-affinity binding and activation of the melanocortin 2 receptor. Synthetic analogs (such as cosyntropin/tetracosactide) utilize this segment.
- C-Terminal Specificity Domain (ACTH 25-39): The species-variable structural segment that confers physiological stability, prolongs systemic half-life, and provides immunological antigenicity without directly mediating steroidogenesis.
- Pituitary ACTH (Eutopic Production): The physiologically regulated hormone synthesized within the anterior pituitary under tight neuroendocrine control by hypothalamic CRH, vasopressin, and systemic cortisol feedback.
- Ectopic ACTH: Pathological, autonomous production of ACTH by non-pituitary neoplastic cells, frequently small-cell lung carcinomas, bronchial carcinoids, or neuroendocrine tumors, devoid of physiological negative-feedback sensitivity.
- Melanocortin Receptor Cross-Reactivity: At excessive concentrations, ACTH binds to the melanocortin 1 receptor (MC1R) on epidermal melanocytes, inducing cutaneous hyperpigmentation due to structural homology with alpha-melanocyte-stimulating hormone (alpha-MSH).
8. Examples & Illustrative Cases
To conceptualize the functioning and pathology of ACTH in clinical medicine, consider the following real-world archetypes:
Case 1: Pituitary-Dependent Hypercortisolemia (Cushing Disease)
A 38-year-old female presents with progressive central adiposity, violaceous abdominal striae, proximal muscle weakness, secondary amenorrhea, and emotional lability. Laboratory investigations reveal elevated 24-hour urinary free cortisol and a high midnight salivary cortisol. Her plasma ACTH levels are inappropriately normal-to-elevated (55 pg/mL; reference range 10-60 pg/mL) despite severe hypercortisolemia, indicating loss of negative feedback inhibition. A high-dose dexamethasone suppression test demonstrates an 80% reduction in urinary glucocorticoids, and pituitary magnetic resonance imaging (MRI) reveals a 4 mm microadenoma in the anterior pituitary. In this case, autonomous, clonal corticotrope proliferation produces excessive ACTH, chronically overstimulating the adrenal glands.
Case 2: Primary Adrenal Insufficiency (Addison Disease)
A 29-year-old male presents with profound chronic fatigue, postural dizziness, unintentional weight loss, salt craving, and striking hyperpigmentation of the palmar creases, buccal mucosa, and surgical scars. Serum electrolytes show hyponatremia and hyperkalemia. Biochemical evaluation reveals an exceptionally low early-morning serum cortisol (1.8 mcg/dL) accompanied by an extraordinarily elevated plasma ACTH level (850 pg/mL). Autoantibodies against 21-hydroxylase confirm autoimmune adrenalitis. Here, destruction of the adrenal cortex eliminates cortisol production, removing the negative-feedback brake on the pituitary. Unrestrained corticotropes flood the circulation with ACTH; the extreme levels cross-activate MC1R receptors on dermal melanocytes, inducing cutaneous hyperpigmentation.
9. Measurement & Assessment
Accurate clinical quantification of ACTH requires rigorous adherence to pre-analytical and analytical protocols due to the peptide’s metabolic fragility and short plasma half-life (approximately 10 to 20 minutes). ACTH is rapidly degraded by circulating proteases; therefore, blood specimens must be collected in pre-chilled tubes containing ethylenediaminetetraacetic acid (EDTA), immediately placed on ice, centrifuged in a refrigerated centrifuge, and frozen at -20°C or colder if analysis is delayed. Modern clinical laboratories quantify ACTH using highly sensitive two-site automated chemiluminescent immunoassays (CLIAs) or immunoradiometric assays (IRMAs) that utilize monoclonal antibodies directed against distinct epitopes on the N-terminal and C-terminal ends, eliminating cross-reactivity with POMC fragments.
Dynamic endocrine testing is standardly employed to evaluate the functional reserve and feedback integrity of the ACTH secretory axis:
- Cosyntropin (ACTH 1-24) Stimulation Test: Evaluates adrenocortical responsiveness. Synthetic ACTH is administered intravenously or intramuscularly, and serum cortisol is measured at baseline, 30, and 60 minutes. An inadequate cortisol peak confirms adrenocortical insufficiency.
- Corticotropin-Releasing Hormone (CRH) Stimulation Test: Differentiates pituitary Cushing disease from ectopic ACTH secretion. Exogenous CRH typically induces an exaggerated rise in plasma ACTH and cortisol in pituitary adenomas, whereas ectopic tumors remain unresponsive.
- Dexamethasone Suppression Tests (Low-Dose and High-Dose): Low doses assess whether cortisol production is autonomous (failure of suppression); high doses assess whether pituitary ACTH can be suppressed by strong synthetic glucocorticoids, distinguishing pituitary sources from ectopic ACTH-secreting tumors.
- Inferior Petrosal Sinus Sampling (IPSS): An invasive catheterization procedure wherein venous blood is sampled directly from the petrosal sinuses draining the pituitary gland compared simultaneously to peripheral blood, before and after CRH stimulation. A central-to-peripheral ACTH gradient greater than 2:1 (or >3:1 post-CRH) confirms a pituitary source of excess ACTH.
10. Applications & Practical Significance
In clinical medicine, understanding ACTH dynamics is central to diagnosing and managing hypothalamic-pituitary-adrenal disorders. Therapeutics targeting the ACTH pathway range from synthetic peptide analogs to receptor modulators. Synthetic ACTH (such as cosyntropin) is widely used diagnostically, but repository ACTH gels are also employed therapeutically as disease-modifying agents in severe pediatric neurological conditions, particularly infantile spasms (West syndrome), and in refractory nephrotic syndrome or acute exacerbations of multiple sclerosis.
In psychiatry and behavioral neuroscience, ACTH dysregulation serves as a prominent biomarker of neurobiological stress vulnerabilities. Major depressive disorder, particularly melancholic depression, is frequently characterized by persistent HPA axis hyperactivity marked by blunted ACTH response to exogenous CRH due to pituitary receptor downregulation, accompanied by non-suppression on the dexamethasone suppression test. Conversely, conditions such as post-traumatic stress disorder (PTSD) and chronic fatigue syndrome often exhibit enhanced negative-feedback sensitivity, resulting in blunted basal ACTH and hypocortisolemic baseline states.
In occupational health and sports physiology, salivary and plasma markers of the HPA axis are evaluated to gauge physiological adaptation, overtraining syndrome in elite athletes, and burn-out phenomena in high-stress professions. Chronically dysregulated ACTH pulses disrupt sleep architecture, impair immune defense by altering peripheral cytokine balance, and accelerate metabolic disturbances including visceral obesity and insulin resistance.
11. Research & Empirical Evidence
Extensive empirical investigations have delineated the precise neurobiological and molecular mechanisms driving ACTH synthesis and regulation. Fundamental research by Wylie Vale and colleagues established that hypothalamic CRH stimulates ACTH exocytosis primarily by binding to the corticotropin-releasing factor receptor 1 (CRHR1), which stimulates adenylate cyclase activity. Subsequent studies demonstrated that arginine vasopressin acts synergistically with CRH via V1b receptors coupled to the phospholipase C-protein kinase C pathway, magnifying ACTH secretion during chronic or severe acute stress.
Clinical trials and observational cohorts led by investigators such as George Chrousos and Philip Gold have highlighted the pathophysiological link between prolonged ACTH-mediated hypercortisolemia and central nervous system remodeling. Sustained elevations in glucocorticoids alter dendritic arborization and reduce neurogenesis within the hippocampus—a key inhibitory regulator of the HPA axis—while simultaneously enhancing synaptic plasticity in the basolateral amygdala. This reciprocal structural alteration leads to a feed-forward neuroendocrine cycle of sustained stress responsiveness.
In pharmacology, major investigations have targeted the melanocortin receptor system. The discovery and functional characterization of the melanocortin receptor accessory protein 1 (MRAP1) by Metherell and colleagues (2005) solved a longstanding enigma, demonstrating that MC2R is completely non-functional without MRAP chaperone activity. Ongoing empirical research focuses on non-peptide, small-molecule antagonists of the ACTH receptor (MC2R) as well as selective CRHR1 antagonists, aiming to provide targeted interventions for Cushing disease, congenital adrenal hyperplasia, and stress-related psychiatric conditions without causing generalized adrenal crisis.
12. Cultural & Cross-Cultural Considerations
While the biochemical sequence and cellular actions of ACTH are biologically universal across human populations, systemic HPA axis reactivity and baseline ACTH dynamics are shaped by cultural, environmental, and socioeconomic variables. Epigenetic studies demonstrate that early-life adversity, systemic discrimination, and socioeconomic deprivation induce enduring alterations in the methylation of the NR3C1 glucocorticoid receptor gene. Individuals raised in chronic high-adversity environments display altered negative feedback sensitivity, resulting in exaggerated or blunted ACTH surges when exposed to acute standardized laboratory stressors, such as the Trier Social Stress Test (TSST).
Furthermore, cultural differences in emotional expression, cognitive appraisal of threat, and social support networks modulate central nervous system perception of stress, directly attenuating or amplifying hypothalamic CRH release and subsequent ACTH output. Cross-cultural psychiatric research highlights that somatic presentations of stress-related illnesses vary widely, yet underlying physiological dysregulations of the neuroendocrine axis remain measurable across diverse ethnic groups, illustrating the dynamic interplay between culturally mediated experiences and neuroendocrine biology.
13. Criticisms, Debates & Limitations
Despite its central place in endocrinology, significant clinical and scientific debates surround the utility and interpretation of ACTH measurements. One major critique concerns the diagnostic reliability of single baseline ACTH determinations. Given the hormone’s short half-life and episodic, pulsatile secretion, a single unprovoked plasma ACTH measurement can vary significantly, often overlapping between normal controls and patients with mild Cushing disease or secondary adrenal insufficiency. Clinicians must therefore rely on dynamic provocation or suppression testing rather than static values.
A continuing controversy in neuropsychiatry involves the historical inconsistency of using HPA axis testing—such as the Dexamethasone Suppression Test (DST)—as a clinical diagnostic tool for depression. While initially heralded in the 1970s and 1980s as a biological breakthrough for diagnosing major affective disorders, wide variations in sensitivity, specificity, and confounding lifestyle factors (including age, weight, smoking, and alcohol intake) ultimately restricted its use primarily to research settings rather than routine clinical psychiatry.
Additionally, debates persist regarding the relative contribution of ACTH-independent mechanisms in adrenocortical regulation. Evidence indicates that direct splanchnic sympathetic neural innervation of the adrenal gland, intra-adrenal paracrine networks, and local immune cytokines (such as interleukin-1 and interleukin-6) can modulate steroidogenesis independently of circulating ACTH concentrations. This demonstrates that while ACTH is the primary endocrine driver, it operates within an integrated, multi-input regulatory network rather than as an isolated linear controller.
14. Related Terms & Distinctions
- Corticotropin-Releasing Hormone (CRH): A 41-amino-acid peptide secreted by the paraventricular nucleus of the hypothalamus that stimulates pituitary synthesis and release of ACTH, functioning upstream of ACTH in the endocrine cascade.
- Cortisol: The primary glucocorticoid steroid hormone secreted by the adrenal cortex in response to ACTH stimulation; acts downstream to regulate metabolism, immune function, and exert negative feedback on ACTH.
- Pro-opiomelanocortin (POMC): The complex precursor prohormone synthesized in the pituitary and brain, which undergoes tissue-specific post-translational enzymatic cleavage to generate ACTH, endorphins, and melanotropins.
- Alpha-Melanocyte-Stimulating Hormone (α-MSH): A tridecapeptide derived from the cleavage of ACTH(1-39) within intermediate pituitary lobes and central neurons; primarily regulates skin pigmentation and energy appetite balance, lacking the adrenal steroidogenic potency of full-length ACTH.
- Cosyntropin: A synthetic drug composed of the first 24 amino acids of human ACTH; exhibits identical steroidogenic activity and is used clinically to evaluate adrenal reserve.
15. Summary & Key Takeaways
Adrenocorticotropic hormone (ACTH) is a peptide hormone produced by the anterior pituitary that plays an indispensable role in maintaining systemic homeostasis. Synthesized from pro-opiomelanocortin under the regulatory control of hypothalamic CRH and arginine vasopressin, ACTH stimulates the adrenal cortex to synthesize and release glucocorticoids. Its secretion exhibits a robust diurnal rhythm and responds rapidly to physical and psychological stressors, subject to tightly controlled negative feedback by circulating cortisol.
Disruptions in the secretion or regulation of ACTH produce significant clinical pathology. Hyposecretion results in secondary adrenal insufficiency, leading to fatigue, hypotension, and potential adrenal crisis. Hypersecretion, whether from pituitary adenomas (Cushing disease) or ectopic neuroendocrine tumors, precipitates systemic hypercortisolemia characterized by metabolic dysfunction, immunosuppression, and psychological disturbances. Comprehensive evaluation through advanced immunoassays and dynamic endocrine testing remains essential for accurate diagnosis and clinical management of neuroendocrine disorders.
References
- Chrousos, G. P. (2009). Stress and disorders of the stress system. Nature Reviews Endocrinology, 5(7), 374–381. https://doi.org/10.1038/nrendo.2009.106
- Metherell, L. A., Chapple, J. P., Cooray, S., David, A., Becker, C., Rüschendorf, F., Naville, D., Begeot, M., Khoo, B., Nürnberg, P., Huebner, A., Cheetham, M. E., & Clark, A. J. (2005). Mutations in MRAP, encoding a new interacting partner of the melanocortin 2 receptor, cause familial glucocorticoid deficiency type 1. Nature Genetics, 37(2), 166–170. https://doi.org/10.1038/ng1501
- Nakanishi, S., Inoue, A., Kita, T., Nakamura, M., Chang, A. C., Cohen, S. N., & Numa, S. (1979). Nucleotide sequence of cloned cDNA for bovine corticotropin-beta-lipotropin precursor. Nature, 278(5703), 423–427. https://doi.org/10.1038/278423a0
- Newell-Price, J., Bertagna, X., Grossman, A. B., & Nieman, L. K. (2006). Cushing’s syndrome. The Lancet, 367(9522), 1605–1617. https://doi.org/10.1016/S0140-6736(06)68699-6
- Vale, W., Spiess, J., Rivier, C., & Rivier, J. (1981). Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science, 213(4514), 1394–1397. https://doi.org/10.1126/science.6267699